TNFRSF10A and cancer: However, susceptibility of human normal hepatocytes to TRAIL was reported recently [30], therefore agonists against DR4 or DR5 (e.g. anti-DR5 antibody) by activating apoptosis signal are becoming dramatically meaningful as candidate drugs for cancer therapy.